iShares US Pharmaceuticals ETF

  • IHE

400 Howard Street,
San Francisco , CA, 94105

Rank

Rank Universe
8 23

Summary

The fund seeks to replicate the total return performance of the benchmark index before fees and expenses by investing in companies across any size in the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

As part of its strategy, the fund employs a passive or indexin More

Webiste

Directors

Jun 14, 2023
  • John E. Kerrigan
  • Richard L. Fagnani
  • Robert S. Kapito
  • Drew E. Lawton
  • John E. Martinez
  • Salim Ramji
  • Madhav V. Rajan
  • Jane D. Carlin
  • Cecilia H. Herbert

Chief Compliance Officer

  • Charles Park

Price

  • $ 68.49 ( -0.68 )
  • Dec 09, 2024
    Last Close
  • Net Assets
  • $630M
    Feb 23, 2024
  • 52-Week High/Low
  • $70.4 - $62.7

  • Expense Ratio
  • -

Performance

YTD

0%

3 Year

-62.94%

5 Year

-55.35%

Best

145.62%

2000

Worst

-64.99%

2024

Company Name

Holding

ELI LILLY AND COMPANY 23.55 %
JOHNSON & JOHNSON 22.68 %
PFIZER INC. 4.56 %
VIATRIS INC. 4.51 %
ZOETIS INC. 4.45 %
BRISTOL-MYERS SQUIBB COMPANY 4.42 %
MERCK & CO., INC. 4.29 %
ROYALTY PHARMA PLC 4.19 %
CATALENT, INC. 4.17 %
ELANCO ANIMAL HEALTH INCORPORATED 2.92 %
More 2.92 %

Documents

Prospectus

link

Annual Reports

link

NAV

Annual Return

Alpha - IHE and S&P